One day after Amerin’s Vascepa won an endorsement from the European Society of Cardiology and the European Atherosclerosis Society in updated dyslipidemia treatment guidelines and the US Food and Drug Administration said it will review supplemental new drug application to expand labeling for Vascepa to treat patients with lower triglyceride levels, Amerin CEO John Thero said, “People have been hearing for too long that dietary supplements ‘might work’ at the Citi Biotech Conference in Boston on 4 September. This HBW story looks at how claims since the 70’s have failed to be proved by data and the differences between dietary supplements and drugs.